Interethnic genetic differences in the prevalence of polymorphisms affecting drug-metabolizing enzymes, drug transporters, and receptors are well documented and must be considered within the perspective of individualized pharmacotherapy. Pharmacologically relevant genetic polymorphisms are rarely present or absent exclusively in one of the three major continental populations (African, Asian and European) that have been more extensively investigated. Possible examples are the CYP2C9*2 allele, which has not been reported in Asians, and both TPMT*2 and *3A, which appear to be absent in Africans. In most cases of documented interethnic pharmacogenomic differences, it is the allelic frequency of polymorphic loci which vary across continental populations; the mean variation, however, remains substantially smaller than the variation between individuals comprising these populations. This is not surprising, since only B10% of the total human genetic diversity stems from continental rather than individual differences. Irrespective of whether human 'races' are social constructs without biological meaning, there is overwhelming evidence for genetic admixture in people from different ancestries in most, if not all populations.
African-Americans it is three times less frequent, than TPMT*3C. 7 Even within South America, significant differences in TPMT allele frequencies are observed between neighboring countries: TMPT*3C, which occurs in 1.8% of white Brazilians, has not been detected in Argentinians. 8 To deal with the specificities of pharmacogenomics in our heterogeneous population, Brazilian researchers from various institutions distributed over the five regions of the country established a collaborative network, named Rede Nacional de Farmacogenética/farmacogenômica or REFARGEN (Brazilian National Pharmacogenetics/pharmacogenomic Network). REFARGEN aims to promote close scientific interaction among its members, to establish a multicentered repository of biological samples for pharmacogenomic studies, to create an archive of pharmacogenomic data for the Brazilian population, to provide a forum for public debate of topics pertaining to pharmacogenomics and to play an active role in educational programs directed to the health science students, professionals and public health officials. In 2004, REFARGEN's members have organized symposia in the annual national meetings of the Brazilian societies of Clinical Genetics, Genetics, and Pharmacology and Experimental Therapeutics, as well as in the Congress of the European Societies of Pharmacology (EPHAR2004). Pharmacogenomics in admixed populations, a motivation force behind the creation of REFARGEN, is the topic of a symposium scheduled for the 2005 annual meeting of the American Society for Clinical Pharmacology and Therapeutics. Additional information on REFARGEN's members, activities and organization can be accessed at www.refargen.org.br.
Pharmacology and genetics, the pillars of pharmacogenomics, have a long tradition in Brazil and are represented by national societies with many decades of activity and thousands of members. It is significant that three of the four Brazilian members of the USA National Academy of Sciences are either geneticists (Francisco M Salzano and Warwick E Kerr) or pharmacologists (Sergio H Ferreira), and all the three have been presidents of their respective national societies. Pharmacogenomic investigation raises important ethical questions. Brazil has a structured system for the approval of clinical protocols, based on institutional review boards (IRB), which must be accredited-and are reviewed at regular intervals-by an independent national ethics committee (CONEP) linked to the National Health Council (CNS). This guarantees proper ethical conduct for any project developed in the country. The guidelines for research in human genetics, encompassing pharmacogenomic studies, were updated by the CONEP-CNS system in August 2004 and provide a solid ethical background for Brazilian researchers to contribute data from our population, and meet the challenge of expanding on a global scale, pharmacogenomics' promise of individualized therapy-including in this process developing countries such as Brazil and its large and admixed population, who will now be in a position to benefit from the advances achieved in this field. In this context, REFARGEN's mission is to support Brazilian researchers and their international collaborators in this endeavor.
